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T H E  PROLIFERATION RATES of gliomas may be modulated by the protein kinase C (PKC) signal transduction 
system. The present study was undertaken to further examine the role of PKC system in growth regulation of 
gliomas in vitro by measurement of PKC activity over various phases of tumor growth and by assessing its potential 
ro le  as a signal transduction system induced by serum mitogens and the known glioma mitogens epidermal growth 
fac to r and fibroblast growth factor. All human glioma lines examined, and the rat glioma C6, displayed high PKC 
activity relative to nonmalignant glial cells, which correlated with their proliferation rates over their respective 
grow th phase. Frozen surgical human malignant glioma specimens also displayed high PKC activity. The relatively 
selective PKC inhibitor staurosporine (SP) reduced PKC activity and corresponding growth rates in a dose-related 
m anner. Stimulation of PKC with phorbol esters under different concentrations of serum in the growth medium 
indicated that the high PKC activity, which correlated with their rapid growth rates, is highly susceptible to 
down-regulation by these agents. Epidermal growth factor and fibroblast growth factor increased both PKC 
activ ity  and the growth rate of glioma line A172; addition of SP reduced the growth rate to levels observed in 
SP-treated control tumors, indicating that PKC may be a common signal transduction system induced by these 
mitogens. These results implicate PKC as an important signal transduction system regulating glioma growth, and 
o ffe rs  a potential target for tumor inhibition. (Neurosurgery 31:717-724, 1992)
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P
rotein kinase C (PKC) is a signal transduction system with 
multifunctional capabilities in different cell types (13,14). 
Recent work in our laboratory with established glioma cell 
lin e s , and the data to be presented in the current report using 
fro zen  human surgical specimens, demonstrates that malignant 
gliom as possess high intrinsic activity of the enzyme compared 
v v ith  non-transformed glia, which correlates with their growth 
ra te s  in vitro, and that this activity is susceptible to inhibition 
t> y  a relatively specific inhibitor of PKC, staurosporine (SP) (5). 
rX’tiis  study was undertaken to further explore the role of the 
p K C  system in the growth regulation of gliomas by determining 
p K C  activity during different phases of growth of a series of 
•rapidly growing malignant gliomas (both human and rat) in 
v it ro , and by comparing the effects of the PKC inhibitor SP on 
p K C  activity and growth rates within an individual tumor. The 
g e n in i dependency of glioma growth and PKC activity was 
e >camined, as was the effect that activators of PKC have on both
of these parameters under different serum conditions. We also 
investigated the PKC system as a potential signal transduction 
system used by identified glioma mitogens epidermal growth 
factor (EGF) (11, 20) and fibroblast growth factor (FGF) (8, 9), 
whose receptors are expressed (and in the case of EGF receptor, 
oft n with gene amplification [6, 11]) on these tumors.
MATERIALS AND METHODS
Glioma cell lines
The cell lines A l 72, U178-MG, U373-MG, and U563-MG are 
characterized malignant glioma lines established elsewhere 
(courtesy of V. P. Collins, M.D., Ludwig Institute for Cancer 
Research, Stockholm, Sweden). The rat glioma C6 was also 
used in this study (obtained from the American Type Culture 
Collection, Rockville, MD). These lines were maintained in 
25-ml Falcon tissue culture flasks in medium consisting of Ea-
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gle's minimal essential medium supplemented with 10% fetal 
calf serum (FCS), gentamicin (20 ng/ml), glutamine, pyruvate 
(1 mmol/L), dextrose (0.1%), and essential amino acids buff­
ered to a pH of 7.0 (all medium constituents were purchased 
from GIB CO, Grand Island, NY). At confluency the tumors 
were passaged regularly by gentle trypsinization (0.05% for 10 
min), followed by serum inactivation of trypsin, repeated 
washes with phosphate-buffered saline (PBS), and replating. 
Cells were grown at 37°C in a humidified 5% C 02 incubator. 
All lines in our laboratory were routinely tested for mycoplasma 
contamination. For measurement of PKC activity and growth 
rates during the glioma growth phase, glioma cultures at dif­
ferent stages of growth (corresponding to early logarithmic, 
mid-log, or late logarithmic growth phases, respectively) ad­
herent to culture plates were harvested as below. For PKC 
activity and growth measurements under various treatment 
conditions, cell cultures were treated in mid-logarithmic growth 
phase.
Frozen malignant glioma specimens
PKC activity was measured in specimens obtained from pa­
tients undergoing surgery for diagnosis and/or cytoreduction 
for malignant glioma. The specimens were snap frozen in liquid 
nitrogen and stored at —70°C. The specimens obtained for this 
analysis consisted of histologically proven glioblastoma multi­
forme (four cases) or anaplastic astrocytoma (one case).
Isolation of nontransformed glia
Control normal human glia were obtained from patients 
undergoing surgery to ameliorate intractable epilepsy. Samples 
were obtained separate from the epileptic focus, and glia were 
isolated as previously described (21, 22). In brief, brain cubes 
were incubated with 0.25% trypsin and 20 )ig/ml deoxyribo­
nuclease for 1 hour at 37°C. The dissociated cells were then 
passed through a nylon mesh of 130 |im pore size, and the 
filtrate then centrifuged in Percoll at 15,000 rpm for 30 minutes. 
The visible cell layer was collected, washed, and resuspended 
in feeding medium described above for glioma cells. These cells 
were placed in Falcon flasks of 25 ml capacity. Twenty-four 
hours later, floating oligodendrocytes were removed and plated 
as enriched (>80%) oligodendrocyte preparations for use in 
other studies. Adherent cells, consisting of astrocytes and 
microglia, were allowed to develop morphologically, and were 
subsequently used for the enzyme assay and isozyme analysis 
described below.
In vitro glioma proliferation assay
Our method for determining rates of glioma proliferation has 
been previously published (4). After passage, each cell line was 
seeded at a density of 104 cells in 40 nl of medium on 12-mm 
glass coverslips placed in 24-well culture plates. Coverslips 
were previously coated with 10 ng/ml poly-Hysine to facilitate 
cell adherence. Twelve hours later, after adequate time for cells 
to adhere to the coverslips, the wells were flooded and washed 
with PBS. After addition of 1 ml of feeding medium to each 
well, each of the PKC modulators or mitogens was then added 
to the wells at predetermined concentrations in replicates of
three. At specified intervals, wells were pulsed with 1 nCi 
[3H]thymidine/ml for a period of 6 hours before harvest. For 
the short time-course study of phorbol-12-myristate-13-acetate 
(PMA) on glioma line A172, the above technique was modified 
to use a short pulse of [;,H]thymidine (30 min) at the concen­
tration above to 35-mm Petri dishes containing four coverslips. 
To measure thymidine incorporation for both of these methods, 
the coverslips with adherent cells were washed four times with 
PBS and placed in scintillation vials containing 5 ml of scintil­
lation fluid (Cytoscint, ICN Chemical, Irvine, CA) for determi­
nation in a beta counter. Mean [3]thymidine uptake values and 
corresponding standard errors were then determined from the 
triplicate readings obtained. Control uptake values were com­
pared with treatment groups using a one-way analysis of vari­
ance (ANOVA) and Duncan's multiple comparison (a =  0.05). 
To demonstrate that uptake of [3H]thymidine into cells is a 
reliable index of DNA synthesis, a control experiment was 
performed in which synthesis of DN A  in the glioma cells was 
stopped by treating the cells with 50 ng /m l of Mitomycin-C 
(Sigma Chemical Co., St. Louis, M O) for 30 minutes; cells were 
then washed four times with fresh medium  and pulsed as above 
with [3H]thymidine. Resulting background [3H]thymidine 
counts were negligible.
Protein kinase C assay
Cells grown in 150-mm plates were rinsed twice with ice-cold 
PBS, followed by a rinse with homogenizing buffer containing 
50 mmol/L Tris-HCl, 2 m m ol/L  dithiothreitol, 1 mmol/L 
phenylmethylsufonylfluoride, and 2 m m ol/L  ethyleneglycol- 
bis-(/3-aminoethyl ether) N,N,N',N'-tetraacetic acid (EGTA). 
The cells were then scraped off the culture plates into 2 ml of 
the above solution and homogenized (30 strokes) in a glass 
homogenizer. The homogenate was then centrifuged at 100,000 
X  g for 1 hour. The supernatant was designated the cytosolic 
fraction. The pellet was resuspended in 2 m l of the above buffer 
containing 1% Triton X-100, homogenized (30 strokes), and 
mixed slowly for 30 minutes. This resuspension was then cen­
trifuged at 100,000 X g for 1 hour, and the supernatant des­
ignated as the particulate fraction. All procedures were per­
formed at 4°C. The enzyme fractions were stored at —70°C 
before assay for PKC.
The method used to assay for PKC activity (phosphate trans­
fer into lysine-rich histone) is modified from the procedure of 
Neary et al. (12), after having determined the correct Michaelis- 
Menten conditions for all cofactors and substrate. The reaction 
mixture contains (final concentrations): 50 m m o l/L  Tris-HCl, 
100 nmol/L free calcium, 250 n g /m l lysine-rich type IIIS his­
tone, 500 ng/m l phosphatidylserine, 25 ixg/m\ diacylglycerol 
(dioctanoyl-sn-glycerol), 10 nm o l/L  ATP (mixed with 
[32P]ATP, 0.5-1 X 106 cpm), 10 m m ol/L  M gCl2, and 4 nl °f 
enzyme preparation. The pH  of the reaction mixture is 7.4 in a 
final volume of 40 nl- The enzyme preparation (particulate or 
cytosolic fraction) is preincubated with the reaction mixture 
minus ATP and MgClz at 30°C for 2 minutes. Phosphorylation 
of histone is initiated by adding ATP and M gC l2, and allowed 
to proceed at 30°C for 1 minute. The reaction is terminated by 
placing a 25-nl aliquot of the mixture onto a 1 X  2 cm phos-
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phocellulose paper (Whatman P81). Each paper is quickly 
transferred to a beaker containing 75 mmol/L phosphoric acid. 
After three washes in phosphoric acid (5 min each) to remove 
unreacted [32P]ATP, the strips are dehydrated with absolute 
methanol, air-dried, placed in vials containing 5 ml of scintil­
lation fluid, and counted for radioactivity. Negative blanks 
(non-PKC-dependent reaction) consist of reaction mixture mi­
nus calcium (in presence of EGTA), phosphatidylserine, and 
diacylglycerol. PKC-dependent reaction is calculated as the dif­
ference between activity in the presence and absence of cal­
cium, phosphatidylserine, and diacylglycerol. Each enzyme 
preparation is analyzed in triplicate, with subsequent determi­
nation of mean values and corresponding standard errors. Re­
sults are expressed as pmol ATP transferred/min/mg protein. 
Variability between triplicates, and between assays, is less than 
10% of the mean in most cases. All reagents were purchased 
from Sigma Chemical Co., with the exception of [gamma- 
32P]ATP, which was purchased from New England Nuclear 
(Wilmington, DE).
To reliably compare activity between cell types, all samples 
were run at 1 j-ig of protein in the reaction mixture. When results 
are expressed as total PKC activity, this represents the sum of 
the cytosolic and particulate activity within the same cell line.
Modulation of glioma growth in vitro
Serum and PKC modulators
To assess the effects of serum on growth rates and PKC 
activity, tumors were grown in medium containing varying 
amounts of FCS for use in the assays described above. The 
effects of inhibition of PKC activity on the growth rate was 
assessed by using the PKC inhibitor staurosporine (SP) (19) 
(Calbiochem, La Jolla, CA) which was dissolved in ethanol and 
further diluted in PBS; it was used over a range of concentra­
tions from 1 to 100 nmol/L. 4-/3-Phorbol-12,13~dibutyrate 
(PDB) and PMA (Sigma), which are phorbol esters and activa­
tors of PKC (1, 10), were administered at doses of 100 nmol/L 
each. As a phorbol ester control, 4-a-phorbol-12, 13-dideca- 
noate (a-PDD) (Sigma), a phorbol ester that binds but does 
not activate the enzyme, was used at a concentration of 100 
nmol/L.
Glioma mitogens
To assess the effects of known mitogens on PKC activity and 
glioma growth, the glioma mitogens FGF (Boehringer Mann­
heim, Indianapolis, IN), isolated from bovine brain, using the 
technique of Gospodarowicz et al. (7), and EGF (Boehringer 
Mannheim) were added to glioma medium to achieve final 
concentrations of 20 and 100 ng/ml each.
RESULTS
PKC activity varies with the growth phase of the 
tumor
Figure 1A depicts total PKC activity (expressed as pmol ATP 
transferred/min/mg protein in the reaction mixture) in several 
human gliomas and the rat C6 tumor grown in 10% FCS- 
containing medium. Activity levels increased in logarithmic
stages of tumor growth. Thymidine uptake was noted to follow 
a similar pattern to the PKC activity when measured over the 
same intervals during the growth phase in vitro. As shown in 
Figure IB, frozen surgical tumor specimens (1-88, 2-88, 5-88, 
6-88,1-158) displayed high PKC activity in the same range as 
the maximal PKC activity obtained in the glioma cell lines 
(A172, U178, U373, U563, C6). Specimens 1-88, 2-88, 5-88, 
and 6-88 are histologically diagnosed glioblastoma multiforme, 
and 1-158 an anaplastic astrocytoma. All tumors expressed 
high levels of PKC activity in comparison with non-trans- 
formed glial controls (astrocyte/microglial total activity was 42 
pmol ATP/min/mg protein, or 10- to 100-fold less than the 
activity measured in the tumors).
PKC inhibition and growth rates
The administration of the relatively selective PKC inhibitor 
SP produced a dose-related decrease in PKC particulate fraction 
activity in glioma line A172 (Fig. 2, top). The cytosolic activity 
remained unchanged; therefore total activity decreased as with 
the particulate fraction. When thymidine uptake was measured 
over the same concentration range, the proliferation rate was 
found to decrease in a similar manner as the total and partic­
ulate PKC activities (Fig. 2, bottom).
Serum effects on glioma growth
To further establish the relation between tumor growth rate 
and PKC activity, selected tumors were grown in reduced (1­
5%) or serum-free media. As expected, reducing the amount of 
serum in the medium reduced the amount of thymidine uptake 
in the same tumor line under control conditions (measured with 
a 6-hr pulse 48 hr after the medium was changed) (Fig. 3A). 
Direct measurement of PKC activity in glioma line A172 under 
different serum conditions revealed a marked reduction in con­
trol PKC activity in cultures grown in serum-free medium as 
compared with cultures grown in 10 % FCS-containing medium 
(Fig. 3B, compare time 0 at top and bottom). The activity mea­
sured in the tumor grown under serum-free conditions, how­
ever, was still far greater than activity in nontransformed glia.
Effects of PKC activation in gliomas under different 
growth conditions
In contrast to the decrease in cell proliferation seen with the 
administration of an inhibitor of PKC, the effect of the PKC 
activators PDB and PMA depended upon the basal growth rate 
of the tumor as determined by the serum concentration of the 
glioma medium (glioma line A172; Fig. 3A). In serum-free me­
dium, where the growth of the tumor is much slower, the 
activators enhanced proliferation (thymidine uptake measured 
24 hr after the addition of 100 nmol/L PMA), whereas in the 
presence of 5% serum, the basal rate of proliferation was greater 
and treatment with phorbol esters produced a decrease in 
growth rate.
Measurement of PKC activity (Fig. 3B) revealed that after the 
addition of PMA in serum-free medium, an initial activation 
phase, characterized by a rapid and marked increase in partic­
ulate and total activity, was followed by a diminution of total 
and particulate activity (top). In contrast, measurement of ac-
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FIGURE 1. PKC activity varies with the growth phase of the glioma. Shown is measurement of total PKC activity 
(expressed as pmol ATP transferred/min/mg protein) over early logarithmic, mid-log, and late-log phases for a series of 
human malignant gliomas and the rat C6 glioma (A, left). Activity increased in the later phases of tumor growth. The 
growth rates as measured by [3H]thymidine incorporation over the same phases of growth followed a similar pattern to 
the PKC activity (A, right). Surgical malignant glioma specimens also display high PKC activity within the range as that o f  
the malignant glioma lines (S) (surgical specimens designated 1-88, 2-88, 5-88, 6-88, are glioblastoma multiforme by h is -  
topathology, 1-158 is an anaplastic astrocytoma; established glioma cell lines are A172, U178, U373, U563, and C6). V a l­
ues are means of triplicates + SEM.
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F IG U R E  2. PKC inhibition in glioma line A172 by SP. Ad­
m in is tra tio n  of the PKC inhibitor SP produced a dose-re­
l a t e d  decrease in PKC particulate fraction activity in glioma 
l in e  A172 (top). Cytosolic activity is unaffected; therefore 
t o t a l  activity decreased as with the particulate fraction. Val­
u e s  are mean of triplicates, with SEM <10%  of the mean in 
m o s t  cases. W hen thymidine uptake was measured over 
t h e  same concentration range (after a 2-day incubation be­
f o r e  the  thymidine pulse), the proliferation rate was found 
t o  decrease in correspondence with the particulate PKC 
a c t iv ity  (bottom). Values are means of triplicates ± SEM.
t iv ity  in the presence of 10% FCS-containing medium indicates 
a prompt down-regulation of the higher initial PKC activity, 
w h ic h  is reflected by an immediate decrease in thymidine in­
corporation (bottom) as previously described (5).
The growth rate of rat glioma C6, in variance to the human 
tum o r , was inhibited by 100 nmol/L PMA in both serum-free 
a n d  serum-present conditions [Fig. 3C, top (serum-free) and 
bottom (10% FCS)]. Direct measurement of the PKC activity 
ind icated an immediate down-regulation of the enzyme under 
b o th  of these conditions. Again, alterations in enzyme activity 
w e re  associated with similar changes in the growth rate of the 
tum o r .
G lio m a  mitogens and PKC activity
Figure 4 depicts experiments in which two known mitogens 
fo r  gliomas, FGF and EGF, were added to glioma line A172. 
O v e r  the 48-hour treatment period, the proliferation rates in­
creased significantly from that of control cultures. The addition
of the PKC inhibitor SP at 50 nmol/L to cultures containing 
these mitogens significantly decreased the growth rates (by 
89.6% and 84.9% in EGF- and FGF-stimulated cultures, re­
spectively) (Fig. 4A). The absolute growth rate obtained by the 
addition of SP to EGF- and FGF-treated cultures was not sta­
tistically different from that of control cultures exposed to SP, 
indicating that the maximal reduction of PKC-mediated growth 
produces a constant basal proliferation rate, independent of the 
initial rate of growth of the tumor.
PKC activity measured after the addition of EGF, 20 ng/ml, 
revealed a rapid increase in cytosolic activity in glioma line 
A172 (Fig. 4B). Particulate activity showed a modest increase 
over the 24-hour treatment period.
DISCUSSION
This study extends observations regarding the role of the 
PKC signal transduction system in modulating glioma growth. 
As noted previously, all glioma lines tested displayed high 
levels of PKC activity in comparison with non-transformed glial 
controls (astrocytes, oligodendroglia, and microglia). In this 
study, the PKC activity was shown to correlate with 
[3H]thymidine uptake within given tumors at different phases 
of tumor growth. Measurement of high PKC activity in human 
malignant glioma surgical specimens suggests this high PKC 
activity may also be functional in vivo.
The ability of the relatively selective PKC inhibitor SP to 
markedly reduce the proliferation rate and PKC activity of 
glioma line A172 in a dose-related fashion further supports the 
evidence that intrinsic high PKC activity of glioma cells corre­
lates with their rapid growth rate. The mechanism of stauro­
sporine inhibition of PKC activity has not been precisely re­
solved, although it has been suggested that it competes with 
high affinity for the ATP binding site of the enzyme (18, 19). 
It is an extremely potent inhibitor of PKC, with an ICS0 of 2.7 
nmol/L in isolated enzyme fractions in vitro (19). Recent work, 
however, suggests that it may also inhibit other tyrosine-spe­
cific protein kinases, especially when used in higher concen­
trations. For example, the tyrosine kinase activity of the platelet- 
derived growth factor receptor may also be partially inhibited 
in Swiss 3T3 fibroblasts in concentrations of 10-7 mol/L range, 
which may facilitate the decrease PKC activity by inhibiting the 
hydrolysis of phospholipase C, the enzyme responsible for the 
generation of diacylglycerol (the endogenous activator of PKC) 
(18). '
Under reduced serum conditions, both growth rates and PKC 
activity within a given tumor are decreased, as demonstrated in 
both the human A l 72 tumor and the rat C6 glioma. In the Al 72 
tumor line, the low activity is amenable to transient stimulation 
in the presence of a pharmacological activator such as PMA or 
PDB, which results in a corresponding transient increase in 
growth rate. However, in serum-containing medium, PKC ac­
tivity increases and is associated with a more rapid growth rate; 
this elevated PKC activity is then susceptible to a more rapid 
down-regulation by the pharmacological PKC activators (2), 
producing a paradoxical inhibition of growth. Results from this 
study are consistent with previous reports which indicate that 
the alteration of in vitro glioma growth rates induced by phorbol
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Serum-Dependency of Activation of PKC 
in Glioma Line A172
Serum—Free Medium
Treatment of Glioma Line A172 with the 
PKC Activator PMA in Serum-Free Medium
Treatment of Glioma Line C6 with the 
PKC Activator PMA in Serum-Free Medium
1 % FCS Medium
Control PMA PDB
5% FCS Medium
Treatment of Glioma Line A172 with the 
PKC Activator PMA in 103$ FCS Medium
Treatment of Glioma Line C6 with the 
PKC Activator PMA in 10fc FCS Medium
i ­
S"
FIGURE 3. Activation or down-regulation of PKC is dependent upon glioma cell line and basal PKC activity. Administra­
tion of the phorbol esters and PKC activators PMA and PDB (both at 100 nmol/L) stimulated A172 tumor growth under 
serum-free medium conditions {A, top), but in contrast decreased growth rates in the presence of 5%  FCS-containing m e ­
dium  (A, bottom). The addition of a-PDD (100 nmol/L), a phorbol ester that binds but does not stimulate PKC, produced 
no significant change in growth rates in all media tested. Values are means of triplicates + SEM. *, values significantly dif­
ferent from controls (one-way ANOVA, Duncan's multiple comparison, P <  0.05). To determine corresponding PKC activ­
ity, serial measurements were obtained over several time intervals in tumor line A172 after the administration of 100 
nm ol/L  PMA^Under serum-free conditions (B, top), initial low activity was stimulated for several hours (which was associ­
ated with a transient stimulation of tumor growth), followed by down-regulation at 24 hours. In 10% FCS-containing m e­
dium , the higher initial PKC activity is immediately down-regulated, and was associated with a prompt inhibition of tu m o r  
growth (B, bottom) as described previously (5). In contrast to the effect of serum upon PKC activation of glioma line A 1 7 2 , 
the rat glioma C6 was inhibited by 100 nmol/L PMA in both serum-free and 10% FCS conditions (C, top and bottom). 
[3H]thymidine counts followed a similar pattern to PKC activity under both conditions. Values are means of triplicates, 
with SEM < 10%  of the mean in most cases.
esters is dependent upon the serum concentration used in the 
culture medium. Under serum-free conditions, PMA and PDB 
act as mitogens for the A172 tumor (16, 17), while in the 
presence of high serum concentrations they inhibit growth (3­
5). That the PKC system is selectively involved in these growth 
rate changes induced by the phorbol esters known to activate 
PKC (PMA and PDB) is supported by the findings that a phor­
bol ester that binds, but does not activate PKC (a-PDD) (1,10), 
does not alter the rates of growth. In contrast to the human 
A172 line, the rat C6 tumor in this study displayed a higher 
intrinsic PKC activity in the absence of serum, which was im­
mediately down-regulated by PMA without an intervening a c ­
tivation phase, resulting in only an inhibition of growth u n d e r  
these conditions.
The observations of the expression of messenger RNA for t h e  
platelet-derived growth factor receptor (15), and amplification 
of the EGF receptor gene (11) in malignant gliomas poses tine  
question of how signals from factors acting through such r e ­
ceptors may be transduced into altered proliferation rates; ir t  
this regard intracellular signal transduction systems are likely t o  
play a pivotal role (20). In the present study, the ability of S P  
to totally block the mitogenic effect of the known glioma rrvi-
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P ro life ra tive  Effects of Glioma Mitogens EGF and FGF 
are Blocked by the PKC Inhibitor Staurosporine
EGF
Control SP . EGF EGF + SP
FGF
> 200 ---------------------------
^ Control SP FGF FGF + SP
Protein Kinose C Activity of Glioma Line A172 
Following Treatment With EGF
B  Period of Treatment with 20 ng/ml EGF
E 4 . Inhibition of PKC blocks proliferative effects of 
g l io m a  mitogens EGF and FGF. Under serum-free 
o n s ,  the addition of EGF (top) and FGF (bottom) at a 
f  1 0 0  ng/ml increases the proliferative rate of glioma 
7 2  (A). Values are means of triplicates + SEM. *, val- 
n if ic a n t ly  different from controls (one-way ANOVA, 
n ' s  multiple comparison, P <  0.05). Concurrent ad- 
a t i o n  of SP (50 nmol/L) reduces the proliferative rate 
p r o d u c e d  by SP alone (values not significantly differ­
*  =  0.05). PKC activity measured after addition of 
:o g e n  EGF at 20 ng/ml to glioma A172 shows an im- 
e  increase in PKC activity, predominately in the cy- 
f r a c t io n  (B). A similar pattern, but of less magnitude, 
sn  in the particulate fraction. Values are means of 
t e s ,  with SEM < 10%  of the mean in all cases.
togens FGF and EGF, and the ability of EGF to increase PKC 
activity implicate PKC as a potential common signal transduc­
tion mechanism induced by these mitogens.
Whether the high intrinsic PKC activity of these tumors rep­
resents a primary defect in the PKC enzyme system per se, or 
an altered regulation of the enzyme activity secondary to the 
aberrant growth factor or receptor genes known to exist in these 
tumors, remains to be determined. Regardless of the resolution 
of this important question, this overexpressed enzyme activity 
may represent a potential future site for chemotherapeutic tar­
geting in these tumors.
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COMMENTS
The role of protein kinase C (PKC) in the signal transduction 
pathway in the growth of human gliomas has been of signif­
icant interest. It would appear that PKC is at higher levels in 
gliomas than in non-malignant glial cells. Epidermal growth 
factor (EGF) and fibroblast growth factor (FGF) appear to play 
a part in growth regulation of gliomas. FGF is a highly consistent
and effective stimulator of growth. EGF at times can down 
regulate certain tumors. FGF appears to be an autocrine growth 
factor in gliomas.
In this paper, the interrelationship between these potentially 
important growth factors and the PKC pathway are explored. 
The data suggests strongly that EGF and FGF increase PKC 
activity as well as the growth rate of glioma lines. A selective 
PKC inhibitor, staurosporine reduced PKC levels and corre­
sponding growth rates. The findings therefore support the hy­
pothesis that the PKC signal transduction pathway is part of the 
system that regulates glioma growth.
This type of research effort, which focuses on specific peptide 
modulators of glioma growth and the targets of their effects, is 
very interesting and provides the types of insights needed to 
identify new avenues for altering the growth of malignant 
gliomas.
Paul L. Kornblith
New York, New York
In this paper Couldwell et al. have expanded upon their 
previous work published in this journal regarding growth reg­
ulation of gliomas and the PKC system. In this study, as in their 
previous study (1), they have shown increased PKC activity in 
a number of human glioma cell lines, in rat glioma C6, and in 
frozen human malignant glioma specimens. They have shown 
decreases in PKC activity and in tumor growth in dose related 
fashion with the known PKC inhibitor staurosporine, and this 
is postulated as a potential therapeutic agent for human inves­
tigation. Much of this encouraging work was alluded to in their 
last paper. When attention is turned to the phorbol esters PDB 
and PMA (which are activators of PKC) the implications are not 
as clear. With these agents, tumor growth is enhanced under 
slow growth conditions (serum-free) but is decreased under 
high growth conditions for the human A172 cell line. In rat 
glioma C6, phorbol esters inhibit growth under both conditions. 
This paradox is explained by a down-regulation hypothesis as 
outlined in their previous paper, and I would direct the reader 
to Dr. Sawaya's previous comments oil it.
The last new finding in this study that differs from the pre­
vious work is the demonstration that glioma mitogens FGF and 
EFG stimulate PKC activity effectively in these tumors. The fact 
that this occurs, and the ability to reverse this effect with stau­
rosporine, does lend credence to the authors' contention that 
PKC is an important signaling mechanism in tumor growth, and 
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